Cite
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma.
MLA
Hersey P, et al. “A Randomized Phase 2 Study of Etaracizumab, a Monoclonal Antibody against Integrin Alpha(v)Beta(3), + or - Dacarbazine in Patients with Stage IV Metastatic Melanoma.” Cancer (0008543X), vol. 116, no. 6, Mar. 2010, pp. 1526–34. EBSCOhost, https://doi.org/10.1002/cncr.24821.
APA
Hersey P, Sosman J, O’Day S, Richards J, Bedikian A, Gonzalez R, Sharfman W, Weber R, Logan T, Buzoianu M, Hammershaimb L, Kirkwood JM, & Etaracizumab Melanoma Study Group. (2010). A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer (0008543X), 116(6), 1526–1534. https://doi.org/10.1002/cncr.24821
Chicago
Hersey P, Sosman J, O’Day S, Richards J, Bedikian A, Gonzalez R, Sharfman W, et al. 2010. “A Randomized Phase 2 Study of Etaracizumab, a Monoclonal Antibody against Integrin Alpha(v)Beta(3), + or - Dacarbazine in Patients with Stage IV Metastatic Melanoma.” Cancer (0008543X) 116 (6): 1526–34. doi:10.1002/cncr.24821.